CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole
Open Access
- 1 October 2000
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 14 (10), 1259-1266
- https://doi.org/10.1046/j.1365-2036.2000.00840.x
Abstract
Background: CYP2C19 has an important role in the catabolism of several proton pump inhibitors. However, the relative contribution of CYP2C19‐mediated metabolism varies among the different proton pum...Keywords
This publication has 47 references indexed in Scilit:
- Review article: the pharmacology of rabeprazoleAlimentary Pharmacology & Therapeutics, 1999
- Eradication of ‘ooHelicobacter pylori‘ox : an objective assessment of current therapiesBritish Journal of Clinical Pharmacology, 1997
- Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugsEuropean Journal of Gastroenterology & Hepatology, 1996
- Genetic polymorphism of S-mephenytoin 4??-hydroxylation in African-AmericansPharmacogenetics, 1996
- Pharmacokinetics, Metabolism and Interactions of Acid Pump InhibitorsClinical Pharmacokinetics, 1996
- Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcerGastroenterology, 1996
- Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitorPharmacogenetics, 1996
- Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole.Gut, 1995
- Combined gastric and oesophageal 24‐hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole.Alimentary Pharmacology & Therapeutics, 1990
- Effect of varying pH on the susceptibility ofCampylobacter pylori to antimicrobial agentsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989